Evidence map›Paper›PMID 34592041›Full record

ArticleJournal of thrombosis and haemostasis : JTH2022

Protein disulfide isomerase-A1 regulates intraplatelet reactive oxygen species-thromboxane A

Kamil Przyborowski, Anna Kurpinska, Dagmara Wojkowska, Patrycja Kaczara, Joanna Suraj-Prazmowska, Kamil Karolczak, Agata Malinowska, Agnieszka Pelesz, Agnieszka Kij, Ivars Kalvins and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. The crucial role of thromboxane AFrontiers in pharmacology · 2026
    Review
  3. Review
  4. Article
  5. Platelets welcome a new protein disulfide isomerase family member.Journal of thrombosis and haemostasis : JTH · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Kamil PrzyborowskiJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0002-8526-945X
Anna KurpinskaJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0003-2130-0099
Dagmara WojkowskaDepartment of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland.ORCID 0000-0002-9317-9817
Patrycja KaczaraJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0003-0106-4172
Joanna Suraj-PrazmowskaJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0002-0190-2474
Kamil KarolczakDepartment of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland.ORCID 0000-0001-5866-7244
Agata MalinowskaMass Spectrometry Laboratory, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warszawa, Poland.ORCID 0000-0001-6599-901X
Agnieszka PeleszJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0002-7907-7750
Agnieszka KijJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0003-2233-0564
Ivars KalvinsLaboratory of Carbocyclic Compounds, Latvian Institute of Organic Synthesis, Riga, Latvia.ORCID 0000-0001-6076-7818
Cezary WatalaDepartment of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland.ORCID 0000-0002-5627-7872
Stefan ChlopickiJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.ORCID 0000-0002-2878-3858
Jagiellonian University · PLMedical University of Lodz · PLInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLLatvijas Organiskās Sintēzes Institūts · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatelet-derived protein disulfide isomerase 1 (PDIA1) regulates thrombus formation, but its role in the regulation of platelet function is not fully understood.

aimsThe aim of this study was to characterize the role of PDIA1 in human platelets.

methodsProteomic analysis of PDI isoforms in platelets was performed using liquid chromatography tandem mass spectometry, and the expression of PDIs on platelets in response to collagen, TRAP-14, or ADP was measured with flow cytometry. The effects of bepristat, a selective PDIA1 inhibitor, on platelet aggregation, expression of platelet surface activation markers, thromboxane A

resultsPDIA1 was less abundant compared with PDIA3 in resting platelets and platelets stimulated with TRAP-14, collagen, or ADP. Collagen, but not ADP, induced a significant increase in PDIA1 expression. Bepristat potently inhibited the aggregation of washed platelets induced by collagen or convulxin, but only weakly inhibited platelet aggregation induced by TRAP-14 or thrombin, and had the negligible effect on platelet aggregation induced by arachidonic acid. Inhibition of PDIA1 by bepristat resulted in the reduction of TxA

conclusionsPDIA1 acts as an intraplatelet regulator of the ROS-TxA

Indexed as

Blood PlateletsProtein Disulfide-IsomerasesHumansPlatelet AggregationProteomicsReactive Oxygen SpeciesThromboxane A2ThromboxanesProtein Disulfide-IsomerasesReactive Oxygen SpeciesThromboxane A2Thromboxanesbepristatflow cytometryPDIs expressionplatelet activationproteomics

Identifiers

PMID34592041
PMCPMC9292974
OpenAlexW3203968448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.